![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number : 1435G Celsis International PLC 17 October 2008 For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: Notifications of Major Interests in Shares 1. Identity of the issuer or the underlying issuer CELSIS INTERNATIONAL of existing shares to which voting rights are PLC attached: 2. Reason for notification (yes/no) YES An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify):______________ 3. Full name of person(s) NORTH ATLANTIC VALUE subject to notification LLP(AS INVESTMENT obligation: MANAGER/ADVISOR) 1. ORYX 4. Full name of shareholder(s) INTERNATIONAL GROWTH (if different from 3): FUND LIMITED 2. NORTH ATLANTIC VALUE LLP (AS INVESTMENT MANAGER) 10 OCTOBER 2008 5. Date of transaction (and date on which the threshold is crossed or reached if different): 13 OCTOBER 2008 6. Date on which issuer notified: TOTAL HOLDING 7. Threshold(s) that is/are INCREASED THROUGH 7% crossed or reached: 8: Notified Details A: Voting rights attached to shares Class/type of shares Situation previous to the triggering Resulting situation after the triggering transaction If possible use ISIN code transaction Number of shares Number of voting Number of shares Number of voting rights Percentage of voting rights rights Direct Indirect Direct Indirect ORDINARY SHARES SEDOL: B0CD5F6 HOLDER 1 HOLDER 2 1,500,000 1,500,000 1,500,000 1,500,000 6.85% 0 0 50,000 50,000 0.23% TOTAL 7.07% B: Financial Instruments Resulting situation after the triggering transaction Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting period/date that may be acquired rights (if the instrument exercised/converted) Total (A+B) Number of voting rights Percentage of voting rights 1,550,000 7.07% 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: NOT APPLICABLE Proxy Voting: 10. Name of proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: NORTH ATLANTIC VALUE LLP IS THE INVESTMENT MANAGER/ADVISOR IN RESPECT OF THE FULL 7.07% HOLDING AS IT IS INVESTMENT MANAGER TO HOLDER 1 AS WELL AS THE OTHER CLIENT INCLUDED IN HOLDER 2. 14 Contact name: BONITA GUNTRIP 15. Contact telephone number: 020 7747 5681 For notes on how to complete form TR-1 please see the FSA website. This information is provided by RNS The company news service from the London Stock Exchange END HOLUBOSRWKRRAAA
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions